

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	2	Attorney Docket Number	5941-65-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5914269	06/22/99	Bennett et al.	
	2	6794392	09/01/04	Suzuki et al.	
	3	2003/0190689	10/01/03	Crosby et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	4	EP 1236474	09/04/02	MAX PLANCK GESELLSCHAFT		
	5	EP 1510221	03/02/05	MITSUBISHI PHARMA CORP		
	6	WO 02/05791	01/24/02	PHARMACIA & UPJOHN SPA		
	7	WO 03/101491	12/11/03	MITSUBISHI PHARMA CORP		(translated abstract)
	8	WO 2004/046386	06/03/04	GENOMIC HEALTH INC		
	9	WO 2004/111273	12/23/04	GENOMIC HEALTH INC		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.A./

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	2	of	2	Attorney Docket Number	5941-65-PUS

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. ¹	
	10	BROGNARD et al., Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research, 2001, Vol. 61, pages 3986-3997.
	11	CAPPUZZO et al., EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small lung cancer. Journal of Thoracic Oncology, 2007. Vol. 2, pages 423-429
	12	DZIADZUISZKO et al., "Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small cell lung cancer patients treated with chemotherapy. Annals of Oncology, 2007, Vol. 18, pages 447-452
	13	HIRSCH et al., Combination of EGFR gene copy number and protein expression predicts outcome for advanced non small cell lung cancer patients treated with gefitinib. Annals of Oncology, 2007, Vol. 18, pages 752-760.
	14	KUWADA et al., "Effects of Trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells" International Journal of Cancer, John Wiley & Sons, Inc. March 20, 2004, pages 291-301
	15	SAITO et al. Proc. Natl. Acad. Sci. USA. April 1999, vol. 96, pages 4592-4597
	16	Supplementary European Search Report for European Application No. 05755989.0, dated July 2, 2009 (Attorney's Reference No. 2848-70-PEP)
	17	Official Action for U.S. Patent Application No. 11/781,946, mailed July 27, 2009 (Attorney's Ref. No. 5941-65-PUS-CIP)

Examiner Signature	/Sean Aeder/ (01/20/2010)	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.A./